A Lean, Efficient Machine (1)(4)(5)
The CTCL market is incredibly concentrated: 60% of these patients live in just 10 states.
The company isn't building a bloated, expensive sales force. Instead, they are using an AI-powered sales platform and a focused field force (~25 reps) to
reach the small, concentrated group of specialists who treat the majority of these cases. This means more revenue hits the bottom line instead of being eaten up by overhead.
Financial Snapshot: A Path to Revenue (1)(2)(3)(4)(5)
The recently reported Fiscal Year 2025 financial results highlight a company that has successfully optimized its spending as it shifts to commercial
operations:
- Strategic Cash Management: The company reported $4.3 million in cash (as of Sept 30, 2025) but raised approximately $61 million in gross proceeds during and after the fiscal year to fuel the launch.
- Insider Alignment: A massive $26.5 million has been committed by company founders, showing ultimate alignment with shareholders.
- Optimized
R&D: R&D expenses dropped to $9.2 million (from $11.9M in 2024), signaling that the heavy spending of the trial phase is over.
- Commercial Readiness: While they did not report revenue for FY 2025, the launch in December 2025 means the revenue engine is now officially turned on.
The "Margin of Safety": Multi-Billion Dollar Pipeline Assets (1)(2)(3)(4)(5)
Mino-Lok®: Potential Standard-of-Care Shift While the oncology launch is the current headline, the "back of the house" holds a potential blockbuster in Mino-Lok®.
- The Breakthrough: This is the first and only antibiotic lock solution designed to salvage infected central venous catheters (CVCs). Currently, the only option for these
patients is "remove and replace"—a painful, risky, and expensive procedure.
- Clinical Superiority: In its Phase 3 trial, Mino-Lok significantly outperformed hospital-standard anti-infective locks, achieving all primary and secondary endpoints with a $p$-value of 0.0006.
- The Market: The global market for catheter-related infections is estimated to exceed $2
billion.
Halo-Lido: The First-in-Class Prescription Play Citius is also targeting a massive "invisible" market with Halo-Lido.
- The Opportunity: Over 10 million Americans report symptoms of hemorrhoidal disease annually, yet there are currently zero FDA-approved prescription products for relief.
- Phase 2b Success: The
proprietary cream formulation showed a meaningful reduction in symptom severity compared to individual components alone.
- The Path Forward: The dose for Phase 3 has been selected, and the company is actively discussing the pivotal study path with the FDA.
The Bottom Line
The jump from "research" to "revenue" is the hardest leap in the industry.
This team just landed it. Coverage is thin, and the
narrative hasn't caught up to the facts on the ground. But when the quarterly numbers start reflecting real-world adoption and international expansion, that "window" usually slams shut.
